Market Overview

UPDATE: Piper Jaffray Initiates Cadence Pharmaceuticals at Neutral, Generics Likely to Continue Gaining Traction

Share:

In a report published on Wednesday, Piper Jaffray analyst David Amsellem initiated coverage on Cadence Pharmaceuticals (NASDAQ: CADX) with a Neutral rating and a price target of $7.00.

In the report, Piper Jaffray noted, "In our survey of nearly three dozen surgeons, the vast majority polled use a multi-modal approach to post operative pain (i.e., opioids, local analgesics like bupivacaine, non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen). Given this backdrop, and the risks related to opioids, it was not surprising to us that just under half of those we polled are already using Ofirmev (albeit still in a minority of patients), and over a third of those polled are planning to use Ofirmev more frequently in the next 6-12 months. Given this feedback, and the fact that Ofirmev is not an opioid and does not have the bleeding risks that hamper NSAIDs, we believe U.S. sales north of $225M by 2015 and peak sales of $450M-$500M are realistic."

Cadence Pharmaceuticals closed on Wednesday at $7.64.

Latest Ratings for CADX

DateFirmActionFromTo
Feb 2014DowngradesBuyNeutral
Feb 2014DowngradesBuyNeutral
Feb 2014DowngradesOutperformNeutral

View More Analyst Ratings for CADX
View the Latest Analyst Ratings

Posted-In: David Amsellem Piper JaffrayAnalyst Color Initiation Analyst Ratings

 

Related Articles (CADX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CISNBairdDowngrades10.0
WDAYSociete GeneraleUpgrades
BKUDA DavidsonInitiates Coverage On39.0
JDVertical GroupInitiates Coverage On
WWells FargoMaintains123.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Exclusive: VeriFone Shares in 'No Mans Land' After Dismal Earnings

UPDATE: Sterne Agee Initiates Costco Wholesale with Buy on Long-term Structural Advantages